This company has been acquired
FRLN Stock Overview
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Freeline Therapeutics Holdings plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.48 |
52 Week High | US$8.70 |
52 Week Low | US$2.11 |
Beta | 0.66 |
11 Month Change | 1.25% |
3 Month Change | 1.73% |
1 Year Change | -21.67% |
33 Year Change | -97.13% |
5 Year Change | n/a |
Change since IPO | -97.60% |
Recent News & Updates
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18Shareholder Returns
FRLN | US Biotechs | US Market | |
---|---|---|---|
7D | -0.2% | -1.2% | 1.6% |
1Y | -21.7% | 22.9% | 30.6% |
Return vs Industry: FRLN underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: FRLN underperformed the US Market which returned 20.5% over the past year.
Price Volatility
FRLN volatility | |
---|---|
FRLN Average Weekly Movement | 3.5% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FRLN's share price has been volatile over the past 3 months.
Volatility Over Time: FRLN's weekly volatility has decreased from 17% to 4% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 152 | Michael Parini | www.freeline.life |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy.
Freeline Therapeutics Holdings plc Fundamentals Summary
FRLN fundamental statistics | |
---|---|
Market cap | US$28.25m |
Earnings (TTM) | -US$49.93m |
Revenue (TTM) | US$622.00k |
45.4x
P/S Ratio-0.6x
P/E RatioIs FRLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FRLN income statement (TTM) | |
---|---|
Revenue | US$622.00k |
Cost of Revenue | US$0 |
Gross Profit | US$622.00k |
Other Expenses | US$50.55m |
Earnings | -US$49.93m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -11.45 |
Gross Margin | 100.00% |
Net Profit Margin | -8,027.65% |
Debt/Equity Ratio | 0% |
How did FRLN perform over the long term?
See historical performance and comparison